Remix Therapeutics Claimed Company
Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Powered by our proprietary REMaster technology platform, we can now create medicines with the unique ability to alter the way genes are read from the genome, correcting dysregulation or eliminating the gene message altogether. These are innovative therapeutic solutions with the potential to address disease drivers at their origin. read more
Heather Wasserman — Chief Business Officer/ Chief Operating Officer at Remix Therapeutics
Executive Bio
Heather is responsible for corporate business development and operations at Remix. She joins after 7 years at Eli Lilly, where she gained extensive business knowledge while heading up immunology search and evaluation, emerging technologies and innovations and most recently global corporate business development during her tenure there. Heather received a PhD from the University of Georgia, and went on to complete a postdoctoral fellowship at Emory University. Heather is excited to work alongside Remix’s talented team focused on novel small molecule modulation of RNA processing.
Executive Team Culture Ratings from Remix Therapeutics Employees
TOP
5%
Remix Therapeutics' Executive Team scores in the Top 5%
of similar sized companies on Comparably
of similar sized companies on Comparably
Remix Therapeutics' Executive Team at a Glance
Based on 66 ratings, Remix Therapeutics' employees are very satisfied with their Executive Team and give them an “A+” or 93/100. On average, Women provided higher ratings for their Executive Team compared to Men. Also, the Biomolecular Sciences and Lead Discovery department thinks more highly of the Executive Team relative to the Discovery Biology department.
Remix Therapeutics' Executive Team ranks in the Top 5% of other companies in Boston and Top 5% of other companies on Comparably that also have 51-200 Employees.
×